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HypertensionExtracellular matrix proteins form the basic structure of blood vessels. Alongwith providing basic structural sup-
port to blood vessels, matrix proteins interact with different sets of vascular cells via cell surface integrin or non-
integrin receptors. Such interactions induce vascular cell de novo synthesis of newmatrix proteins during blood
vessel development or remodeling. Under pathological conditions, vascular matrix proteins undergo proteolytic
processing, yielding bioactive fragments to inﬂuence vascularwallmatrix remodeling. Vascular cells also produce
alternatively spliced variants that induce vascular cell production of different matrix proteins to interrupt matrix
homeostasis, leading to increased blood vessel stiffness; vascular cell migration, proliferation, or death; or vascu-
lar wall leakage and rupture. Destruction of vascular matrix proteins leads to vascular cell or blood-borne leuko-
cyte accumulation, proliferation, and neointima formation within the vascular wall; blood vessels prone to
uncontrolled enlargement during blood ﬂow diastole; tortuous vein development; and neovascularization
from existing pathological tissue microvessels. Here we summarize discoveries related to blood vessel matrix
proteins within the past decade from basic and clinical studies in humans and animals — from expression to
cross-linking, assembly, and degradation under physiological and vascular pathological conditions, including
atherosclerosis, aortic aneurysms, varicose veins, and hypertension.righam and Women's Hospital,
USA. Tel.: +1 617 525 4358;
.© 2014 Elsevier B.V. All rights reserved.1. Introduction
Blood vessels deliver oxygen and nutrients to body tissues. The
major constituent of the vessel wall is the extracellular matrix (ECM),
collectively known as stroma or matrix. In arteries or veins, the ECM
constitutes more than half of the wall mass and contains mainly colla-
gens and elastin. Other vascular wall constituents include ﬁbronectin,
microbifrils (mainly ﬁbrillins), abundant amorphous or soluble proteo-
glycans, and leucine-rich glycoproteins. The normal blood vessel wall
contains several functionally distinct types of vascular matrices, includ-
ing subendothelial basement membrane, intima, media, adventitia, and
interstitial matrix. Each of these vessel sections contains different types
of cells and matrix proteins.1.1. Vascular wall ECM components
All vessel lumens are lined with endothelial cells (ECs) that are
anchored on an underlying basement membrane, a thin sheet-like
structure containing mainly laminin, type IV collagen, nidogen,
perlecan, type XV and type XVIII collagens, ﬁbronectin, heparin sulfateproteoglycan perlecan, and other macromolecules [1–3]. At least 20
ECM proteins have been identiﬁed from basement membrane prepara-
tions. Most of these proteins, if not all, have tissue-speciﬁc functions.
Underneath the basement membrane is the intima, which separates
ECs from the internal elastic laminae (IEL) formed by several layers of
contractile vascular smooth muscle cells (SMCs) and separated by elas-
tic ﬁbers and collagen-rich ECM. Under the basement membrane, nor-
mal vessels contain minimal intima, and instead contain media
beginning at the IEL, followed by concentric lamellar units composed
of elastic ﬁbers and SMCs separated by interlaminar matrix collagens,
microﬁbrils, proteoglycans, glycoproteins, and ground substance [4] —
although the media components can be different between different
types of blood vessels. Arteries, for example, have more collagens and
elastin than veins have. Outside the SMC layer of large vessels is an ad-
ventitial layer extending beyond the external elastic laminae and inter-
stitial matrix that contains ﬁbrillar types I and III collagen, chondroitin
sulfate and dermatan sulfate proteoglycans, ﬁbronectin, and many
other ECM proteins.
The same ECM proteins at different regions of the blood vessel wall
may come from different cells and be regulated by differentmodulators
under certain circumstances. Collagen and elastin in the media are
produced primarily by SMCs. TGF-β1 stimulates SMC proliferation, mi-
gration, and ECM expression, leading to luminal narrowing [5]. Attenu-
ating TGF-β1 activity with tranilast, TGF-β3, or directly with TGF-β1
inhibitors diminishes intima SMC proliferation-associated thickening,
often called blood vessel stenosis or restenosis [6,7]. In the adventitia,
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primarily come from ﬁbroblasts, as in other connective tissues. In cul-
tured rat adventitial ﬁbroblasts, vascular endothelial growth factor
(VEGF) regulates the expression of osteopontin, an integrin recognition
sequence arginine–glycine–asparagine (RGD)-containing ECM phos-
phoprotein that mediates leukocyte cell adhesion and migration, and
prevents cell apoptosis.
Different ECM proteins form different types of blood vessels. Mature
vessel wall ECM is a complex arrangement of ﬁbrous proteins, associat-
edwith glycoproteins embedded in a hydrated ground substance of gly-
cosaminoglycans and proteoglycans. Normal large arteries also contain
collagen, elastin, ﬁbronectin, and small amounts of osteopontin,
thrombospondin, and tenascin. Vessel wall remodeling occurs as an ad-
aptation to pressure and ﬂow (e.g., vein graft) or to mechanical
(e.g., angioplasty) or biochemical (e.g., atherosclerosis) injuries, all of
which promote ECM-regulated SMC migration and proliferation [8].
Arterial SMCs also synthesize vitronectin. Normal quiescent vessels
contain only low levels of interstitial vitronectin and ﬁbronectin.
Vitronectin receptorαvβ3 andαvβ5 integrins, and ﬁbronectin receptor
αvβ3 andα5β1 integrins, are suppressed in quiescent SMCs [9]. In nor-
mal arteries, apolipoprotein E (ApoE) and ApoE-containing high-
density lipoprotein (HDL) maintain arterial elasticity by controlling
the expression of ECM, reducing the expression of collagen-1, ﬁbronec-
tin, and the elastin/collagen cross-linking enzyme lysyl oxidase in
response to substratum stiffening. In angiogenic vessels, however,
ﬁbronectin also becomes a predominant constituent of the endothelial
basement membrane. Angiogenic vessels, but not quiescent vessels,
also contain ﬁbronectin alternative spliced variants: extra domain-A
(ED-A) and extra domain-B (ED-B).
1.2. ECM functions
ECM is not an inert supporting network, but rather an active and dy-
namic structure with a fundamental role in regulating vascular function
in normal and pathological conditions. One ECM protein may regulate
the production of others. Homeostasis of the vascular ECM may affect
intrinsic properties of the arterial wall and arterial stiffness. When elas-
tin scaffold and collagen scaffoldwere prepared from porcine ascending
aortas [10], and implanted subdermally into live rats for 28 days, por-
cine elastin scaffolds contained enhanced rat collagen ﬁbers and bun-
dles, and porcine collagen scaffolds contained elevated rat elastin
ﬁbers — indicating that elastin and collagen support de novo ECM syn-
thesis [11].
Cellular interaction with ECM regulates cell adhesion, migration,
proliferation, phenotype, and tissue architecture under different cir-
cumstances. From in vitro prepared SMCs, total insoluble ECM proteins
stimulate RAW264.7 or thioglycolate-elicited macrophage extracellular
signal regulated kinase-1/2 (EKR1/2) activation, cyclooxygenase (COX)-
2 and prostaglandin (PG) E2 syntheses, and protease (e.g., urokinase
plasminogen activator [uPA] and matrix metalloproteinase [MMP]-9)
expression. The selective COX-2 inhibitor NS398 blocked ECM-induced
protease expression. Macrophages from COX2-deﬁcient mice showed
reduced responses to SMC-ECM, demonstrating that COX-2 is an ECM
target [12]. Vascular cells use matrix receptors such as integrins to de-
tect changes in matrix rigidity and composition that occur during tissue
remodeling. The resulting intracellular signaling then regulates cellular
processes such as proliferation, survival, differentiation, and gene ex-
pression [13]. The basal laminae proteins collagen-IV, laminin, and
perlecan limit SMCgrowth, enhance contractile gene expression, reduce
inﬂammatory gene expression, reduce low-density lipoprotein (LDL)
uptake in culture, and inhibit matrix calciﬁcation. In contrast, interstitial
matrix proteins— such as collagen-I, collagen-III, ﬁbronectin, and osteo-
pontin — enhance SMC growth concomitant with elevated ERK phos-
phorylation and expression of cell cycle regulators [14,15]. Inhibiting
the integrins that bind to these interstitial matrix proteins sufﬁciently
blocks SMC proliferation in response to platelet-derived growth factor(PDGF), epidermal growth factor (EGF), and basic ﬁbroblast growth fac-
tor (bFGF) [16], and reduces migration and neointima formation in vivo
[17]. Collagen-IV, polymerized collagen-I, proteoglycans, and media
elastin limit SMCgrowth and promote a contractile phenotype,whereas
monomeric collagen-I reduces contractile gene expression.
As we will discuss further later, damage to ECM components con-
tributes to the development of vascular diseases. ECM components
such as elastin and proteoglycans undergo fragmentation or physio-
chemical alteration during atherogenesis. Chemically modiﬁed ECM or
enzymatically degraded ECM may change the activities of parental
ECM, thereby promoting ECM remodeling and vascular disease patho-
genesis. Many ECM subdomains have roles independent of the parental
ECM molecules; they therefore are often called matrikines, and have
pathophysiological functions. Fragments from the noncollagenous
(NC1) domain of the type IV collagen α1, α2, and α3 chains (also
known as arresten, canstatin, tumstatin), type XV collagen (also
known as restin), and type VXIII collagen (also called endostatin) all
have anti-angiogenic activities to block neovascularization [18,19]. Pro-
duction of these matrikines directly affects the angiogenesis that plays
physiological roles in embryogenesis and pathological roles in tumor
growth, atherogenesis, abdominal aortic aneurysms (AAAs), varicose
veins, hypertension, and many other large and small artery and vein
disorders.
2. Elastin
Mature elastin is an insoluble and hydrophobic protein formed by
cross-linking of its precursor, tropoelastin — a 68–74 kDa monomeric
protein from elastin mRNA alternative splicing normally produced by
SMCs in the media and by ﬁbroblasts in the adventitia, released to the
extracellular space for cross-linking and elastin ﬁber formation with
the assistance of lysyl oxidase and the helper proteins ﬁbulin-4 or -5.
Elastin deposition is limited to the media layer extending from the in-
ternal to external elastin laminae. Elastin is the dominant ECM in the ar-
terial wall, comprising 50% of its dry weight [20], and is the largest
component of elastic ﬁber, comprising ~90% of elastic ﬁber total weight.
Elastin ﬁber consists of ﬁbrillin microﬁbrils and is embedded within an
amorphous core of elastin that allows the elastic recoil. Arteries are sub-
ject to extensivemechanical stress induced by arterial blood pressure. In
addition to mechanical integrity, elastic laminae contribute to the elas-
ticity of the arteries. Recoil of the arterial wall therefore is a critical
mechanism for the continuation of bloodﬂowduring diastolewhen car-
diac ejection is ceased. Fibrillin-rich microﬁbrils provide a structural
scaffold to guide elastin deposition and assembly. Elastic ﬁbers are
found throughout the vessel wall in the medial layer, where they ar-
range in concentric fenestrated elastic laminae. Each elastic lamina al-
ternates, and is physiologically connected with a concentric ring of
SMCs, forming the lamellar unit— the functional resilient unit of the ar-
terial wall [21,22].
Under normal conditions, elastogenesis is restricted mainly to fetal
life and infancy, and mature elastic ﬁbers last for the entire lifespan.
The half-life of elastin ﬁbers is about 40 years; elastic ﬁbers are consid-
ered the most durable element of ECM [23]. Elastic ﬁbers are degraded
and fragmented with age and disease, leading to increased stiffness of
the arterial wall [24]. Under pathological conditions, vascular cells
(SMCs, ECs, and ﬁbroblasts) make elastin as part of the reaction to in-
creased mechanical stress [25]. In addition to vascular cells, inﬂamma-
tory cells also produce tropoelastin, but these tropoelastins fail to
cross-link into elastic ﬁbers [26].
2.1. Elastin expression, cross-linking, and assembly
The human tropoelastin gene is located on chromosome 7. Its ex-
pression can be regulated differently in response to different cytokines,
growth factors, or other bioactive molecules. Insulin-like growth factor
(ILGF), transforming growth factor (TGF)-β1, cGMP, and nitric oxide
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growth factor, interleukin (IL)-1β, angiotensin (Ang)-II, hypoxia, and
age suppress elastin expression. After synthesis, tropoelastin trafﬁcs
from the cytoplasm to the extracellular space for cross-linking and as-
sembly, a process mediated by a 67 kDa elastin-binding protein (EBP),
which protects tropoelastin from intracellular aggregation and proteol-
ysis. After ﬁnishing its delivery, EBP is recycled to the cytoplasm to
chaperon the next tropoelastin molecule [27] (Fig. 1).
The primary structure of tropoelastin contains hydrophobic domains
that include the non-polar amino acids glycine, valine, proline, and ala-
nine, and cross-linking domains that are rich in alanine and lysine. All
lysines on tropoelastin are subjected to oxidative deamination or
cross-linking by lysyl oxidase [28]. The copper-dependent enzyme
lysyl oxidase subjects the epsilon-amino group of the targeted lysine
to deamination, producing the alpha-amino adipic delta-semialdehyde
allysine [29] (Fig. 2A). Under non-enzymatic condensation, one lysine
molecule and one allysine molecule form a Shiff base lysine–allysine
dimer, whereas two molecules of allysine form an allysine–allysine
methylacrylaldehyde derivative (Fig. 2B). Three allysine and one lysine
form desmosine or isodesmosine (Fig. 2C); both are markers of elastin
cross-linking. After cross-linking, tropoelastin forms polymers that con-
stitute the concentric rings of elastic lamellae around the arterial lumen.
Such cross-links help organize the tropoelastin peptide chains into a ﬁl-
amentous network structure for the storage of recoiling energy under
mechanical stress. Elastin assembly occurs at microﬁbrils that contain
non-elastin components of the elastin ﬁbers [30], such as ﬁbrillins and
microﬁbril-associated glycoproteins (MAGPs). These microﬁbrils pro-
vide a scaffold for tropoelastin deposition, alignment, and cross-
linking [20]. After the organized deposition of tropoelastin at themicro-
ﬁbril, the ﬁnal enzymatic cross-linking process ensues (Fig. 1).Fig. 1. Tropoelastin synthesis, binding with elastin-binding protein (EBP), transport, release of
and ﬁnal formation of an elastic ﬁber with microﬁbrils.2.2. Elastin activities
Elastin acts as more than an arterial wall structural protein for the
storage of recoiling energy. In vitro, many cells exhibit migration and
proliferation in response to tropoelastin, elastin degradation products,
and elastin peptides. Unlike other ECMcomponents, such as collagen,ﬁ-
bronectin, and laminin, elastin does not interact with integrin [31]. Vas-
cular cells such as SMCs, and likely other cell types as well, express a
non-integrin elastin/laminin receptor, which directly interacts with
elastin and mediates elastin-induced cellular activities [32]. This elastin
receptor has three subunits: 67 kDa EBP, 61 kDa neuraminidase, and
55 kDa protective protein [31]. Elastin may use this receptor to regulate
target cell migration, chemotaxis, proliferation, myoﬁbrillar organiza-
tion, and anti-inﬂammatory activities.
Elastin elicits inhibitory effects on SMC migration and proliferation.
In vitro, SMC proliferation and migration on collagen gels were signiﬁ-
cantly reduced by elastin degradation peptides in a dose-dependent
manner [33]. SMC migration was suppressed on elastin peptide-coated
surfaces, comparedwith those cultured on surfaces coatedwith collagen
or ﬁbronectin [34]. SMCs grown on elastin-coated substrates also prolif-
erated much less than those grown on uncoated substrates [35]. In vivo,
elastic ﬁbers and laminae prohibited SMC proliferation and prevented
intimal hyperplasia [36]. In a rat model of adventitial implantation of
collagen, basal lamina, and elastic laminae patches, elastic laminae
patches— but not laminin or collagen patches— are associated with re-
duced neointima formation and SMC proliferation [37]. In a porcine cor-
onary model of in-stent restenosis, stents coated with elastin sheaths
prepared from carotid artery digestion elicited inﬂammatory and
thrombotic responses lower than those from uncoated stents [38].
Growing vascular SMCs on elastin preserved the quiescent, contractileEBP, assembly with ﬁbulins, binding to microﬁbrils, lysyl oxidase-mediated cross-linking,
Fig. 2. Elastin cross-linking. A. Lysine oxidation and allysine formation. B. One lysine and one allysine form a Schiff base; two allysines together form a methylacrylaldehyde derivative.
C. One lysine and three allysines cross-link into desmosine or isodesmosine.
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Elastin therefore regulates vascular SMC migration, induces contractile
phenotypes, and inhibits proliferation. An elastin cleavage product
called elastin-derived peptide (EDP) is also biologically active [40]. Al-
though mature elastin ﬁbers are key elements in the maintenance of a
quiescent vascular SMC phenotype by providing a physical barrier for
cellular migration, EDP binds to elastin/laminin receptors [41] and stim-
ulates vasculature proliferation and migration. EDP also promotes the
release and activation of MMPs from inﬁltrated leukocytes [42].
Tropoelastin and elastic ﬁbers induce vascular SMC myoﬁbrillar or-
ganization by activating a novel heterotrimeric G protein-coupled sig-
naling pathway that induces actin ﬁber formation via intracellular Rho
GTPase. On tropoelastin, a discrete hexapeptide domain, VGVAPG,
is sufﬁcient to induce vascular SMC myoﬁbrillar organization. The
hexapeptide domain stimulates a signaling pathway that is indistin-
guishable from that activated by the full-length geneproduct. Therefore,
tropoelastin stimulatesmyoﬁbrillar organization via a direct interaction
between vascular SMCs and the VGVAPG domain [43].
Elasticmatrix is also chemotactic to vascular SMCs andmacrophages,
anti-inﬂammatory on leukocytes, and anti-thrombotic. EBP in aortic tis-
sue extracts (soluble proteins) prepared from amouse model of Marfan
syndrome and from humanswithMarfan syndrome and idiopathic tho-
racic aortic aneurysm(TAA) has chemotaxic activity formacrophagemi-
gration in vitro. When in vitro prepared rat elastic lamina, basal lamina,
and adventitial collagen were implanted into a host artery and exposed
to leukocytes, elastic lamina exhibited anti-inﬂammatory activities.
Compared with the adventitial collagen matrix and basal lamina, elastic
laminae associated with lower leukocyte adhesion, reduced SMC prolif-
eration, and inhibited neointima formation [37]. Pure porcine vascular
tissue elastin scaffold subdermal implantation into rats demonstrated
that these scaffolds were thrombosis-resistant [11]. Elastic laminae
therefore are relatively inﬂammation resistant and/or thrombosis resis-
tant, compared with collagen or laminin matrices.
2.3. Elastin gene mutations and calciﬁcation
Mutation in the elastin gene ELN in humans leads to supravalvular
aortic stenosis (SVAS) and Williams syndrome. SVAS is an autosomaldominant disorder caused by intragenic deletion or a large spectrum
of mutations within the elastin gene [44]. These result in functional
haploinsufﬁciency through nonsense-mediated decay of mRNA from
the mutant allele or the production of nonfunctional protein. In SVAS
patients, therefore, arterial elastic ﬁbers and laminae are composed of
lower elastin levels [45]. These patients have stenosis of the ascending
aorta or other arteries, or arterial narrowing, developed from uncon-
trolled vascular SMC proliferation and intima hyperplasia [36,46]. If
not corrected, SVAS may lead to cardiac hypertrophy and heart failure
[47]. Williams syndrome is a neurodevelopmental disorder with patho-
logical phenotypes similar to SVAS, resulting from submicroscopic dele-
tion within the chromosome 7q11.23, involving the whole ELN gene
[48]. Mice lacking the elastin gene diewithin days of birth from vascular
occlusion due to subendothelial cell accumulation [36]. Vessel obstruc-
tion in these mice occurs due to excessive subendothelial proliferation
and vascular SMC accumulation in the absence of inﬂammatory re-
sponse. As in elastin-haploinsufﬁcient humans with SVAS, elastin-
haploinsufﬁcient Eln+/−mice exhibited thinner arterial elastic laminae,
and thereafter increased medial SMCs [45]. Arterial inner diameters
were generally smaller than normal at any given intravascular pressure.
When damaged during aging or tissue injury, elastic ﬁbers are gen-
erally not replaced, because elastin expression is turned off in adults. In-
stead,more collagens aremade, shifting the arterialwall toward a stiffer
range of collagen ﬁbers. The arterial wall may also stiffen due to calciﬁ-
cation of the elastic lamellae. Calcium deposits in the media in large ar-
teries increase with age. Aortic calcium correlates with arterial stiffness
in humans. In a rat calciﬁcation model, calcium accumulation in the ar-
teries is accompanied by a concomitant increase in pulse wave velocity
(PWV) [49], a measure of large artery stiffness. Additional cross-linking
by advanced glycation end-products (AGEs) can increase the stiffness of
elastin and collagen. AGEs form protein–protein cross-linking on colla-
gens, which prevents collagen enzymatic digestion and increases the
overall collagen in the arterialwall. AGE-mediated cross-linking also oc-
curs in elastin, and increaseswith age in the human aorta [50]. There are
two types of elastin calciﬁcation. In type-1 calciﬁcation, elastin un-
dergoes self-calciﬁcation without structural changes before calciﬁca-
tion. In type-II calciﬁcation, elastin becomes vacuolated with the
accumulation of neutral lipids and unesteriﬁed cholesterol within
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tion or fragmentation. Calciﬁcation of blood vessels was most promi-
nent in small arteries in the cortex of the kidney in young mice
(10 months of age), but in older mice (17 months of age) it also oc-
curred in other areas, such as the aorta and vena cava [51].
3. Collagens
Collagen is a very stiff protein that limits vessel distension. Collagen
includes at least 24 different subtypes and ~38 distinct polypeptide
chains [52], depending on the structures and functions of vessels. Differ-
ent cell types also express different types of collagen. In the normal and
injured arterial walls, type I and type III collagens (collagen-I and
collagen-III) are the main types in the media and adventitia. Arterial
injury may alter the balance between the two types of collagens. For
example, collagen-I in healthy arteries is a heterotrimer α1(I)2α2(I).
Developing skin or healing wounds contain low levels of collagen-I
homotrimerα1(I)3. In patientswith ischemic heart disease, coronary ar-
tery biopsy immunohistology revealed signiﬁcantly reduced collagen-III
expression, reduced collagen-III/collagen-I ratio, and increased elastin/
collagen-III ratio [53].
3.1. Collagen interaction with vascular cells
Collagens also interact with vascular cells (e.g., SMCs, ECs, and ﬁbro-
blasts) and play important roles in vascular cell biology and pathobiol-
ogy. Collagens participate in SMC differentiation, adhesion, migration,
proliferation, and apoptosis. Both β1 integrin and the discoidin-
domain receptor (DDR) family members mediate these collagen activi-
ties [54].α1β1 integrin stimulates SMC proliferation by activating ERKs
in the MAPK pathway [55]. The α2β1 integrin signaling pathway is im-
portant to vascular SMC adhesion, proliferation, and differentiation on
polymerized ﬁbrillar collagens [56]. α10β1 and α11β1 integrins medi-
ate collagen-dependent mesenchymal nonmuscle cell adhesion and
chemotaxis [57,58]. In vivo, depletion of β1 integrin at the onset of
SMC differentiation caused failure to assemble ECM, resulting in lethal-
ity prior to birth [59]. DDR1–collagen interaction also regulated SMCmi-
gration and proliferation, and MMP production [60]. Ddr1−/−mice had
decreased SMC proliferation after vascular injury [61].
SMC contractile gene promoters are active under physiological con-
ditions, but are temporarily silenced in response to injury [62,63].When
rat aortic SMCswere cultured on collagen-IV andmonomeric collagen-I,
collagen-IV stimulated serum response factor (SRF) binding to the pro-
moters of SMC actin andmyosin heavy chain and stimulatedmyocardin
expression, while monomeric collagen-I stimulated SMC expression of
the inﬂammatory adhesion molecule vascular cell adhesion molecule-
1 (VCAM-1), and this collagen-I activity could be inhibited by the NF-
κB inhibitor SN50 [64]. Polymerized but not monomeric collagen-I
regulates SMC apoptosis. When human SMCs were cultured on poly-
merized collagens or monomeric collagens, polymerized collagens in-
creased SMC apoptosis by increasing the production of active MMP-1.
These MMP collagenases may degrade polymerized collagens that in-
duce xIAP (X-chromosome-linked inhibitor of apoptosis, a caspase in-
hibitor) proteolysis. Therefore, collagen fragments released from ECM
by MMP may propagate SMC apoptosis by calpain-mediated inactiva-
tion of anti-apoptotic xIAP [65].While inﬂammatory conditions activate
SMC expression of collagens, collagen matrices stimulate SMC
expression of collagen, elastin, and integrins. High-glucose (22 mM)
or vasoactive Ang-II (100 nM) increased mouse vascular SMC ERK1/2
phosphorylation and induced expression of latent TGF-β1, αvβ3
integrin, and collagen-I release in the medium [66]. When rat aortic
SMCs were cultured on 2-D or 3-D mixtures of different combinations
of collagen-I and ﬁbrin for 7 days, SMCs expressed more collagen-III,
tropoelastin, and α1, β1, and β3 integrins on 3-D matrices than on 2-D
matrices. SMC expressions of tropoelastin and β1 integrin were highest
on collagen matrices. Expressions of collagen-III and β3 integrin werehighest on pure ﬁbrin. Expression of collagen-I was highest on
collagen-I–ﬁbrin composite matrices [67].
Human umbilical vascular endothelial cells (HUVECs) cultured on
collagen-I showed decreased nitrite synthesis, nitric oxide synthase
(NOS) activity, and endothelial NOS (eNOS) protein content and
mRNA, compared with those cultured on collagen-IV. This activity of
collagen-Iwasmediated by its interactionwith integrin on ECs. Interfer-
ences of collagen-I-dependent signals through the integrin-interfering
peptide D6Y or an anti-integrin (α1 or β1) antibody blocked these re-
ductions [68]. When porcine aortic ECs were grown on native or
glycated collagen or exposed to shear stress using an in vitro parallel
plate system, cells on native collagens, but not those on glycated
collagens, elongated and aligned in the ﬂow direction in 24 h of
20 dyn/cm2. Shear stress-mediated NO released from ECs was also re-
duced by 50% when ECs were cultured on glycated collagen, which
was correlated with reduced eNOS phosphorylation, likely by inhibiting
sheer stress-induced focal adhesion kinase activation [69]. In a similar
experiment, when porcine aortic ECs were cultured on native and
glycated collagen-coated substrates in low, normal, and high glucose
conditions, ECs bound to glycated collagens much more tightly than to
native collagens. ECs interact with glycated collagens using αvβ3
integrin, as opposed toα2β1 with native collagen binding [70]. In addi-
tion to NO production and cell adhesion, collagens also affect EC activity
in vasculogenesis.When cultured human umbilical cord blood endothe-
lial progenitor cells (EPCs) were cultured in 3-D collagen matrices for
18 h, in either direct analysis or at an additional 14 days after subcuta-
neous implantation to immunodeﬁcient mice, the results showed that
increased collagen concentration in the 3-D collagenmatrices decreased
vascularization per area, but increased vessel sizes [71].
Fibroblasts also respond differently to various types of collagen. In
cultured rat ﬁbroblasts, collagen-IV induced ﬁbroblast differentiation
into myoﬁbroblasts, while collagen-I and collagen-III induced ﬁbroblast
proliferation. Collagen-I, but not collagen-III, activated ERK1/2 in ﬁbro-
blasts [72].
3.2. Bioactive collagen fragments
When intact collagens affect vascular cell activities, the pathophysi-
ological activities of proteolytic fragments from both type IV and type
XVIII collagens are well characterized. Collagen-IV contains six chains
(α1 to α6), and each has three functional domains: the cysteine-rich
N-terminal 7S domain, the central triple-helical domain, and the globu-
lar C-terminal non-collagenous domain (NCl) (Fig. 3A). The NCl domain
is critical for cellular interaction, matrix association, and network as-
sembly [73]. Three α chains form a collagen-IV protomer (Fig. 3A), the
basic unit of collagen-IV superstructure. Endogenously produced NCl
fragments of human α1 (IV), α2 (IV), and α3 (IV) have been identiﬁed
as anti-angiogenic [74–76], corresponding to 26 kDa arresten, 24 kDa
canstatin, and 28 kDa long tumstatin, respectively (Fig. 3A). When α2
(IV) NCl was added to bovine retinal microvascular ECs, it inhibited EC
early attachment, proliferation, and in vitro angiogenesis, and induced
EC apoptosis and inhibited angiogenesis in an oxygen-induced retinop-
athy (OIR) model [77]. Pentastatin is a 20-amino acid peptide from the
α5 ﬁbril of collagen-IV. It suppressed vessel growth in an angiogenesis
in vitro assay and in an in vivo tumor model (small lung cancer xeno-
graft) [78].
Collagen-XVIII is a 133 kDa non-ﬁbrillar collagen that forms an α-
chain trimer and is located mainly in the basement membrane, in the
perivascular region of blood vessels, and in adult and embryonic basal
laminae. Mice and humanswith defective collagen-XVIII had ocular de-
fects and poor ocular vessel growth [79,80]. Unlike collagen-IV, alterna-
tive splicing at the N-terminal of collagen-XVIII yields two additional
variants with an extra 20 kDa or 44 kDa N-terminal peptide. Endostatin
is a 20 kDa fragment of the C-terminal of collagen-XVIII and has tumor-
suppressing properties [81]. Elastase or cysteine protease cathepsin L
(CatL) generates endostatin by cleaving the collagen-XVIII at the hinge
Fig. 3. Schematic structures of collagen types IV (A) and XVIII (B) and locations of their identiﬁed bioactive peptides.
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[82]. Neostatins are MMP-derived cleavage products of collagen-XVIII.
Neostatin-7 is a C-terminal 28 kDa endostatin-spanning fragment gen-
erated from collagen-XVIII by MMP-7 [83]. MMP-14 (also known as
MT1-MMP) generates 23 kDa neostatin-14 from collagen-XVIII [84]
(Fig. 3B). Murine neostatin-7 inhibits calf pulmonary artery EC prolifer-
ation. Microinjection of neostatin-7 and neostatin-14 naked DNA into
the corneal stroma reduced FGF-induced neovascularization [84].
3.3. Collagen mutation in humans and animals
Mutations, deﬁciencies, or different composites of collagens directly
or indirectly affect the vasculatures. Collagen-I (COL1A1 or COL1A2)mu-
tations in humans cause osteogenesis imperfecta with aortic dilation,
dissection, and rupture [85]. Ehlers–Danlos syndrome (EDS) is an
inherited connective tissue disorder caused by a defect in collagen syn-
thesis. Most EDS subtypes in humans are caused by mutations of
collagen-I, collagen-III, and collagen-V, or in genes responsible for
their post-translational modiﬁcation [86]. Collagen-III pro-collagenmu-
tation (COL3A1) causes EDS [87]. Patients are particularly susceptible to
dilation and rupture of arteries throughout the vasculature. Defects in
collagen-III are responsible for type IV EDS [88]. In humans, collagen-I
homotrimers associate with a pro-α2(I)-chain-defective variant of
EDS [89], and homozygousα1(I) collagen deﬁciency associates with os-
teogenesis imperfecta [90].
The presence of collagen-I homotrimers [α1(I)]3 in mice signiﬁcant-
ly weakens the aorta. Mice with a mutant Col1a1 allele that lacks theﬁrst intron showed reduced age-dependent and tissue-dependent ex-
pression of collagen-I [91]. Mice die at 18 weeks of age, without aortic
dilation as determined by high-resolution magnetic resonance imaging
(MRI); mice with both collagen-I and collagen-III mutations die prema-
turely from ruptured blood vessels [92]. Collagen-VI-dependent basal
lamina assembly is a critical aspect of vessel development. In a B16F10
melanoma tumor model, absence of collagen-VI in mice reduced
vascular basal lamina by twofold, reduced EC sprouting and survival,
increased vessel leakage by threefold, and increased tumor hypoxia
10-fold [93].
3.4. Collagen excessive production, synthesis and degradationmarkers, and
imaging
Excessive collagen in the vascularwall leads to vesselﬁbrosis and in-
creased stiffness. Increased expression of lysyl oxidase is a mechanism
of tissue ﬁbrosis and stiffness [94,95]. High lysyl oxidase expression in-
creases collagen cross-linking and collagen stiffness. TGF-β is another
possible element involved in collagen deposition via stimulation of
ECM synthesis and reduction of its degradation [96]. In a rat common
carotid artery balloon catheter injury model, which involves SMC mi-
gration, proliferation, and neointima formation, elastin synthesis was
twice as much as collagen 7 days after injury, but both signiﬁcantly in-
creased by 21 days and 60 days post-injury. At 60 days, collagen was
nearly twice as much as control artery, and elastin was more than two-
fold as the controls [97]. Expression of collagenase-resistant collagen in
experimental models provided a powerful tool to test the role of
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expressing MMP collagenase-resistant collagen (Apoe−/−Col1a1r/r)
showed increased adventitia collagen content (picrosirius red, masson
trichrome, and α1 pro-collagen mRNA) [98].
Althoughmarkers for synthesis or metabolism have not been identi-
ﬁed for every type of collagen, markers for collagen-I and collagen-III
have been studied thoroughly. C-terminal procollagen type I (PICP)
and free amino-terminal collagen-I pro-peptide (PINP) have been
used as markers of collagen-I synthesis. The telopeptide of collagen-I
(ICTP) is an index of collagen-I degradation, and free amino-terminal
collagen-III pro-peptide (PIIINP) reﬂects collagen-III metabolism.
Oregon green 488-conjugated CNA35 is a collagen-speciﬁc probe.
Administration ex vivo to freshly prepared mouse tissues, or intrave-
nous injection into mice, allowed detection of tissue collagen contents.
In ex vivo tissue culture, CNA35 labeled collagens I, III, and IV as con-
ﬁrmed by antibody immunostaining [99]. Two-photon laser scanning
microscopy allowed the use of speciﬁc dyes for collagen (Oregon
green 488-conjugated CNA35) on isolated intact viable carotid arteries
from mice [100].
4. Fibronectin
Fibronectin is a dimeric multidomain glycoprotein in plasma and in
tissue ECM. This 440 kDa glycoprotein of the ECM is linked by two disul-
ﬁde bonds located at the C-terminus. It is produced and secreted by nu-
merous cell types including SMCs,ﬁbroblasts, andmyoﬁbroblasts, and is
widely distributed in ECM. Fibronectin function in the vasculatures is
mediated byα5β1 integrin, which is expressed by ECs, SMCs, and ﬁbro-
blasts. Fibronectin binding to cell surface α5β1 integrin uses the RGD
sequence within the 10th type III globular β-sheet repeat of ﬁbronectin.
This binding is required for ﬁbronectin matrix assembly and signaling.
4.1. Fibronectin pathophysiological activities
Fibronectin plays roles in cell adhesion, migration, growth, and dif-
ferentiation. Bonemarrow-derived EPCs are involved in vascular repair.
When EPCs were cultured on AGE-modiﬁed ﬁbronectin, cells showed
reduced attachment, spread, and chemotaxis. On wounded retinal mi-
crovascular ECs, EPCs showed clustering at the wound sites, but AGE-
ﬁbronectin reduced this targeting response [101]. Fibronectin in blood
vessels modiﬁes the mean stress and elastic modulus of the vessel
wall, and associates closelywith arterial SMCs to detect and react tome-
chanical forces via integrin receptors [102]. Deposition of ﬁbronectin on
ECM controls the deposition, organization, and stability of other matrix
proteins, including collagen-I, collagen-III, and thrombospondin-1
[103]; and modulates leukocyte inﬁltration, expression of adhesion
molecules, cell proliferation, and SMCphenotype, all which are involved
in vascular remolding [104]. In freshly isolated rat aortic SMCs, when
cells were seeded on ﬁbronectin, cells in serum-free medium remained
in G0/G1 phase for the ﬁrst 6 days with increased expression of cyclin
D1 and p27KIP1. Addition of serum enhanced the expression of cyclins
D1, A, and D3, reduced p27KIP1 expression and retinoblastoma protein
hyperphosphorylation, and promoted cell cycle progression into S
phase. Fibronectin therefore promotes cell cycle entry of SMCs in prima-
ry culture [105].
Plasmaﬁbronectin supports platelet thrombus formation. In amodel
of arterial thrombosis, plasma ﬁbronectin deﬁciency (plasma ﬁbronec-
tin conditional knockout mice) delayed thrombus formation and
growth and subsequent occlusion of injured arteries [106]. In a mouse
arteriole endothelium denudation-induced local vessel injury throm-
botic response model, normal thrombosis was observed in the venules
fromWTmice, but in FN+/−mice, a decrease by half of plasma ﬁbronec-
tin delayed the appearance of thrombi in arterioles and their occlusion.
Giving mice rat plasma ﬁbronectin could prevent this defect.
Fluorescent-labeled plasma ﬁbronectin demonstrated incorporation of
exogenous ﬁbronectin into the developing thrombi [107].4.2. Fibronectin alternative splicing variants
Human ﬁbronectin variants result from RNA alternative splicing of
the IIICS, ED-A, and ED-B segments, which are also known as V, EIIIA,
and EIIIB from rat ﬁbronectin. Each of these ﬁbronectin variants has dis-
tinct effects on the vasculatures or vascular cells. The IIICS segment
alone contains at least four different variants, with or without cell bind-
ing sites CS-1 and/or CS-5. In vitro, ﬁbronectin CS-1 acts like VCAM-1 by
binding to α4 integrin on leukocytes [108], which may indirectly affect
vascular wall remodeling. CS-1 therefore mediates leukocyte adhesion
and chemotaxis. ED-A and ED-B are highly enhanced around newly de-
veloping vasculature during embryogenesis and in pathological condi-
tions. ED-A and ED-B may be important in facilitating SMC phenotype
differentiation [109]. Embryos lacking both ED-A and ED-B are e9.5–
e10.5 lethal [110]. Duringwound healing in the liver, ED-A induced stel-
late cell differentiation intomyoﬁbroblasts and promoted ﬁbrosis [111].
Skin ﬁbroblasts responded to ED-A in vitro to differentiate to a ﬁbrotic
phenotype of myoﬁbroblasts [110]. In vitro, macrophage foam cell for-
mation increased ED-A expression. Macrophages from ED-A-deﬁcient
Apoe−/− mice accumulated less intracellular lipids, suggesting that
ﬁbronectin ED-A contributed to macrophage lipid metabolism and
foam cell formation [112]. In vitro, Ang-II and tumor necrosis factor-α
(TNF-α) induce SMC expression of ED-B [113]. Unlike ED-A, ED-B
plays a regulatory role in the differentiation of immature acinar epithe-
lial cells into type II pneumocytes in lung alveolar [114]. Genetic deple-
tion of ED-B reduced ﬁbroblast growth and ﬁbronectin production
[115], but whether ED-B also affects vascular cell differentiation is
unknown.
5. Fibulins
All seven ﬁbulins, except ﬁbulin-3, have been found during cardio-
vascular development, and mostly are induced after injury. Like most
other vascular wall matrix proteins, ﬁbulins exhibit their functions by
interacting with integrin, but the activity most characteristic of ﬁbulins
is interaction with other ECM proteins, such as elastin, ﬁbronectin,
and proteoglycan. Fibulins participate with ﬁbronectin in blood
clotting. Interaction between ﬁbulins (e.g., ﬁbulin-4 and ﬁbulin-5) and
tropoelastin assists elastin assembly (Fig. 1). Fibulin-1 and ﬁbulin-2
also bind to the C-type lectin-like domain of aggregating proteoglycans
including versican, aggrecan, and probably other lecticans.
Lack of ﬁbulin-4 abolishes elastogenesis. Fibulin-4-deﬁcient
(Fbln4−/−) mice exhibit lung and vascular defects, including emphyse-
ma, artery tortuosity, irregularity, aneurysm, rupture, and resulting
hemorrhage. Mice die prenatally. E12.5 mice show descending aorta
narrowing. Mice do not develop intact elastin, but only contain irregular
elastin aggregates in skin and lung. Desmosine analysis showed that
elastin cross-links in these mice were largely diminished, although ex-
pression of tropoelastin and lysyl oxidase mRNA was not affected in
the lungs [116]. SMCs isolated from SMC-speciﬁc ﬁbulin-4-deﬁcient
mice exhibited an immature SMC phenotype with reduced smooth
muscle-myosin heavy chain and increased proliferation. In mice with
ﬁbulin-4 deﬁciency only in SMCs, aortic wall showed reduced expres-
sion of smoothmuscle-speciﬁc contractile genes, and focal SMC prolifer-
ation with degenerative medial wall. These mice also developed
ascending TAAs and tortuosity, with markedly increased ERK1/2 [117].
Transcription interference through placement of a TKneo targeting con-
struct in a downstream of Mus81 gene generated Fbln4R/Rmice with re-
duced expression of ﬁbulin-4. These mice showed dilation of the
ascending aorta and tortuous and stiffened aorta, resulting from a disor-
ganized elastin ﬁber network. They displayed thickened aortic valvular
leaﬂets with aortic valve stenosis and insufﬁciency [118].
Fibulin-5 (also known as developing arteries and neural crest EGF-
like, DANCE) is an ECM from the blood vessel basement membrane,
ECs, and SMCs that, like ﬁbulin-4, regulates elastic ﬁber assembly. De-
veloping vessels and adult vessels express it prominently; it thereby
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and localizes tropoelastin to microﬁbrils (Fig. 1), and therefore partici-
pates in elastin assembly. Without ﬁbulin-5, elastin cannot form func-
tional ﬁber [119]. In humans, altered expression of ﬁbulin-5 correlated
with thoracic aortic dissection [120]. Studies from organ donors from
TAApatients demonstrated that aortic elastin andﬁbulin-5mRNA levels
decreased. Decreased ﬁbulin-5 expression correlated strongly with de-
creased elastin. Primary cultured SMCs from TAA patients showed a de-
crease in ﬁbulin-5mRNA, comparedwith normal SMCs [120]. Fibulin-5-
deﬁcient (Fbln5−/−) mice displayed enhanced SMC proliferation and
migration [121], loose skin, and tortuous arteries with disrupted elastic
lamellae [119]. Fibulin-5-deﬁcient mice, which lacked functional cross-
linked elastin-containing ﬁbers, abrogated microstructural properties
and the biaxial mechanical response of the common carotid arteries, al-
though multiphoton microscopy revealed only negligible changes in
collagen organization [122].
Fibulin-2 in the vasculature is regulated by injury. Treatment with
peptides (FN III 3–5 and aggrecan C-type lectin-like domain) interferes
ﬁbulin-2 and versican interaction, thereby blocking SMC migration
[123]. In Fbln2−/−Fbln5−/− double-knockout mice, all elastin laminae,
including internal elastic laminae, were severely disorganized, but elas-
tic lamina disruption did not appear in Fbln2−/− mice and was much
milder in Fbln5−/− single-knockout mice. Fbln2−/−Fbln5−/−mice also
had enhanced vascular adhesionmolecules (ICAM-1) and tissue factors,
thrombus formation, marked dilation, and vessel wall thinning after ca-
rotid artery ligation injury [124]. Therefore, ﬁbulin-2, -4, and -5 are im-
portant ECMs in the vascular wall, contributing directly to elastic ﬁber
cross-linking and assembly and associated cell biology.
6. Other vascular ECM proteins
Elastin, collagen, ﬁbronectin, and ﬁbulin have been among the most
studied ECMproteins from the blood vesselwall during the past decade.
But other ECM proteins, such as laminin, ﬁbrillin, ﬁbrinogen, and
vitronectin, also play important roles during vessel wall development
and remodeling, although relatively fewer studies of these proteins
have been performed.
Laminin is a family of large cross-like heterotrimeric glycoproteins
composed of 1 α chain, 1 β chain, and 1 γ chain derived from 11
genes, 5 α chains, 3 β chains, and 3 γ chains. Laminin α4, α5, and α2
are the major isoforms in large blood vessels [125]. We have found
that cysteinyl cathepsin S (CatS) generates 100 kDa, 80 kDa, and
50 kDa proteolytic fragments from the 150 kDa full-length laminin γ2
chain. Both the 100 kDa and 80 kDa fragments were pro-angiogenic in
an in vitromouse aortic ring assay [126]. Monoclonal antibodies against
these γ2 fragments are now widely used to detect microvessels.
Fibrillins are extracellular microﬁbrils that associate with elastic ﬁ-
bers. Both ﬁbrillin-1 and ﬁbrillin-2 interact with elastin, ﬁbronectin,
vitronectin, and collagens. Fibrillin-1 also interacts with integrin recep-
tors [127]. Fibrillin-1 stabilizes elastic ﬁber structure in mature vessels
(Fig. 1). Fibrillin-1 mutation causes postnatal death in mice from vessel
dissection and rupture [128]. In humans, ﬁbrillin-1mutation is linked to
Marfan syndrome [129]. Therefore, ﬁbrillin-1 maintains elastic ﬁber
structure and vessel integrity, stabilizing the interaction between vascu-
lar cells and matrix scaffold. The role of ﬁbrillin-2 in vascular morpho-
genesis or disease, however, remains unknown.
Vitronectin is a glycoprotein found in the circulation and ECM. The
best-known function of this ECM protein is promoting cell adhesion
and spreading. Vitronectin plays a role in arterial wall remodeling
[130], by promoting SMCmigration, but has no effect on SMC prolifera-
tion [131]. Vitronectin also contributes to thrombosis. In themesenteric
arteriole FeCl3-induced injury real-time intravital microscopy thrombo-
sis model, Vn−/− mice had unstable thrombi and greater numbers of
emboli. Vessel occlusion was delayed and frequent vessel re-opening
occurred in Vn−/−mice. In a nitrogen dye laser-induced cremastermus-
cle arteriole injury model, Vn−/−mice had fewer platelets, lower ﬁbrincontent, and more unstable ﬁbrin in the thrombi than did WT control
mice. In vitro, thrombin-induced aggregation was abolished at a low
concentration of thrombin in Vn−/− platelets [132].
Fibrinogen is a 340 kDa plasma protein that is converted into ﬁbrin
during blood clotting. But when porcine ECs were cultured on ﬁbrino-
gen, cells expressed high levels of the chemokines monocyte
chemoattractant protein-1 (MCP-1), PDGF-AB, and IL-8, leading to a
two-fold increase inmonocyte chemotactic activity [133]. In human pa-
tients with primary systemic vasculitis, such as Churg–Strauss syn-
drome (CSS) and Wegener's granulomatosis (WG), blood antibodies
against ﬁbrinogen and vitronectin were increased [134].
7. ECMprotein synthesis and assembly in aortic and venous diseases
ECM proteins are themain structural proteins of large blood vessels,
such as aortic and venous arteries. Here, we provide a brief overview of
ECM production and assembly in few selected large blood vessel dis-
eases — atherosclerosis, AAA, varicose veins, and hypertension.
7.1. Atherosclerosis
Arterial wall elastin and collagen are the best-studied ECMproteins in
atherogenesis. Uncontrolled degradation of these ECMproteins promotes
atherogenesis by increasing blood-borne leukocyte transendothelium
migration, SMC migration and proliferation, neovascularization, vascular
cell apoptosis, and ultimately neointima formation and aortic wall rup-
ture. Elastic ﬁbers are made of elastin molecules organized in long
cross-linkedﬁlaments; their cross-links are desmosine and isodesmosine.
Pyridinoline and deoxypyridinoline— two forms of non-reducible cross-
links — stabilize mature collagen. Change in collagen structure may pre-
dispose to arterial rupture in atherosclerosis.
Human carotid plaques contain reduced elastin. In atherosclerotic
lesions, the inability of the cells within the lesion to produce mechani-
cally stable matrix may lead to plaque rupture. As mentioned earlier,
elastin cross-linking is a prerequisite for elastic ﬁber assembly and is
mediated by lysyl oxidase, which is diminished by inﬂammatory cyto-
kines in human ECs. Atorvastatin and simvastatin, two common statin
medications used as lipid-lowering regimens among hyperlipidemia
patients, increased inﬂammatory cytokine-induced lysyl oxidase ex-
pression reduction in porcine, bovine, and human aortic ECs and abro-
gated reduction of lysyl oxidase in hypercholesterolemic animals
[135]. In a rabbit model of atherosclerotic femoral artery balloon injury,
animals fedwith a lysyl oxidase inhibitor,β-APN, demonstrated increased
femoral artery lysine and decreased desmosine and isodesmosine, indi-
cating inhibition of elastin cross-linking (Fig. 2).
Human aortic intima containsmainly collagen-I and collagen-III, but
also other collagens (e.g., collagen-IV, -V, -VI, -VII, and -VIII) and proteo-
glycan. Laser-induced ﬂuorescent spectroscopy (LIFS) combined with
microscopy, birefringence, and gene expression proﬁling demonstrated
that human carotid plaques contain reduced elastin, but increased
collagen-I and collagen-III. Picrosirius red staining showed the associa-
tion of collagen content with mechanical rigidity of the ﬁbrous cap
[136]. Although SMCs, ECs, and ﬁbroblasts all express collagens, SMCs
are likely dominant in producing collagen in the media. One important
role of SMCs is to stabilize the artery wall by elaborating collagen-I ﬁ-
brils; but in atherosclerotic lesions, SMCs are loaded with lipid, which
may affect SMC biology. In vitro, when SMCs were incubated with LDL
or very low-density lipoprotein (VLDL), the ability of SMCs in collagen
ﬁbril assembly decreased, and ﬁbronectin assembly decreased. Al-
though actin cytoskeleton expression and vinculin-containing focal ad-
hesion complex formationwere unaffected in these SMCs, they failed to
assemble ﬁbrillar adhesion complexes and developed disorganized
clustering ofαvβ1 integrin and tensin [137], a primary component of ﬁ-
brillar adhesion complex that is critical in ﬁbronectin assembly. SMCs
from atherosclerotic lesions thereforemay express a different set of col-
lagens than do healthy aortas. Differential display and RT-PCR of SMCs
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tions from atherosclerosis-prone Apoe−/− mice demonstrated that
collagen-VIII was expressed in atherosclerotic lesion SMCs, but not in
normal SMCs; in situ hybridization showed their expression on the
plaque luminal surface [138]. In a rabbit model of atherosclerotic femo-
ral artery balloon injury, inhibition of collagen cross-linking with a lysyl
oxidase inhibitor β-APN reduced femoral artery tissue extract levels of
pyridinoline and pentosidine. Scanning and transmission electron mi-
croscopy showed profound disorganization of artery collagen ﬁbers
from β-APN-treated mice, with high remodeling index, low neointimal
collagen density, and decreased restenosis [139].7.2. Aortic aneurysms
Elastin degradation is one of the most important signatures of
human AAAs and other small and large blood vessel aneurysms. ELISA
demonstrated that serum elastin peptides were signiﬁcantly higher in
AAA patients than in normal controls. Elastin cross-linking and elastic
ﬁber formation directly affect AAA expansion and rupture. Aortic tissue
extract HPLC analysis showed a reduction of elastin cross-links in
human AAAs [140]. Increase of elastin synthesis or prevention of
elastinolysis helps to stabilize AAA progression. In a rat model of aortic
elastase-perfusion-induced AAA, adenoviral expression of tropoelastin
in vascular SMCs reduced AAA growth [141]. Polyphenolic tannins,
such as pentagalloyl glucose, are novel elastin stabilizing agents.
Tannins bind to elastin and render elastin resistant to enzymatic
degradation [142]. In CaCl2 periaortic injury-induced experimental
AAA in rats after 28 or 56 days, one-time periadventitial delivery of
noncytotoxic pentagalloyl glucose inhibited elastin degeneration and
attenuated AAAs without interfering with inﬂammation (macrophage
and T cell contents), calciﬁcation, or high metalloproteinase activities
[143].
Although media elastin loss is considered a hallmark of AAA, AAA
growth and ultimate rupture also associate with impaired collagen
homeostasis. 3-D confocal imaging showed that collagen ﬁbers are or-
ganized in a loose braiding of collagen ribbons in normal aorta adventi-
tia. These ribbons encage the vessel, allowing it to dilate easily without
overstretching. AAA and aneurysms of Marfan syndrome, however,
show altered collagen architectures with loss of collagen knitting.
Atomic force microscopy showed that the AAA wall lost its ability to
stretch easily, but collagen content changes in aneurysmal lesions
have been controversial. This may be due to the type of collagens and
the methods applied. Plasma ELISA showed that both collagen-IV and
collagen-XVIII levels are signiﬁcantly higher in AAA patients than in
healthy donors or even those with peripheral arterial disease. Colori-
metric analysis and gas chromatography demonstrated that, in human
AAA lesion tissue extracts, levels of the collagen synthesis markers col-
lagen hydroxyproline (4-hypro) and 5-hydroxylysine (5-hylys) were
reduced by 50%, but pyridinoline collagen increased by 350% and
deoxypyridinolines increased by 100%. These observations suggest re-
duced new collagen synthesis but accumulation of old collagen in
human AAA lesions [140]. Picrosirius red staining of aortic tissue sec-
tions from AAAs, aortic dissection (cleavage of wall into two sheets:
the inner half and the outer half), and control patients showed that col-
lagen levels in the inner and outer halves in AAA and aortic dissection
lesions were much lower than those from control patients. Decrease of
collagen content in dissected aortas was mainly located at the external
portion of themedia (site of cleavage), and in aneurysm itwasmore dif-
fused, which is consistent with global expansion. In a rat left common
carotid artery bilateral renal arteries posterior branch ligation-induced
cerebral aneurysms, both RT-PCR and immunohistological analysis
revealed diminished expression of collagen-I, collagen-III, and lysyl
oxidase over time. IL-1β inhibited the expression of collagen-I,
collagen-III, and lysyl oxidase in rat aortic SMCs by activating the NF-
κB pathway [144].7.3. Varicose veins
Depending on the deﬁnition, 14%–50% adults have varicose veins,
and 3%–11% have clinical signs of chronic insufﬁciency, such as eczema,
hyperpigmentation, or ulceration. These conditions result from venous
reﬂux and hypertension due to abnormal dilation of the superﬁcial
veins or deep vein thrombosis, valvular incompetence, and reﬂux
through the perforating veins. The major structural proteins of the
vein wall are collagen, elastin, and SMC actin. Dilatation and enhanced
distensibility are biophysical properties of varicose veins, which can
be detected using ultrasonography.
Histology, morphometric, and tissue microarray of vein wall tissue
in patients with varicose veins showed that varicose veins have signiﬁ-
cant elastin loss in the adventitia and reduced collagen-III in the intima
and media. Elastin loss correlated negatively with vein diameter at rest.
Collagen-III loss in the intima correlated negatively with the increase in
vein diameter during the Valsalva maneuver [145]. In contrast,
collagen-I mRNA levels increase in media from varicose veins [146],
leading to decrease of the ratio of collagen-III to collagen-I that may af-
fect the vein resistance to stretch.
As in the aortic wall, SMCs are important cells that produce elastin,
ﬁbrillin-1, and collagen. Immunostaining and in situ hybridization
demonstrated expression of tropoelastin and ﬁbrillin-1 in SMCs
boarding the elastic laminae, and SMCs expressing these ECM occurred
in patchy disorganized patterns. Varicose veins show high latent TGF-β
binding protein (LTBP)-2 and TGFβ expression, particularly in the
subendothelium and media, and in areas with marked injury. Develop-
ment of varicose veins therefore involves elastin component recon-
struction [147]. Increased TGF-β and LTBP-2 in varicose veins may
regulate SMC expression of elastin and collagens, and these SMCs may
express different sets of ECM than those expressed by healthy veins.
In vitro cultured SMCs from varicose veins showed increased levels of
collagen-I mRNA, but no difference in collagen-III mRNA levels com-
pared with normal vessels [145]. At protein levels, both collagen-III
and ﬁbronectin were decreased in cultured SMCs from varicose veins
due to proteolytic degradation by collagenases, such as MMP-3 [148].
Decreased collagen-III expression in varicose vein SMCs is also respon-
sible for collagen-I overexpression [145]. SMCs from varicose veins
also showed increased proliferation and enhanced matrix mineraliza-
tion, a process that may be mediated by matrix Gla protein (MGP).
MGP is a calcium-binding protein that participates in bone tissue orga-
nization, but this protein is highly expressed in human atherosclerotic
lesions and is increased in plasma from atherosclerosis patients. Plasma
MGP levels increase with age and associate with increasing Framing-
ham coronary heart disease risk score [149]. In vitro, MGP inhibition
or using siRNA reduces varicose vein SMC proliferation [150].
Compared with studies in aortic arteries or microvessels, very little
information is available regarding varicose vein elastin and collagen
degradations. Among proteolysis events, MMPs and their TIMPs have
garnered themost attention and have been linkedwith the pathological
events of varicose veins, but different groups have reported contradicto-
ry observations. Some studies have shown that MMP-1, MMP-2, MMP-
3, MMP-7, TIMP-1, and TIMP-3 increase in varicose veins, but another
study showed reduced expression of MMP-1 and MMP-2 in varicose
veins. We have recently shown that human varicose veins contain
large quantities of cysteinyl cathepsins S, K, L, and B, but reduced levels
of their endogenous inhibitor, cystatin C [151]. Elevated expression of
these proteases in human varicose veins may contribute to reduced
elastin and collagen-III — a hypothesis that, to our knowledge, has not
been tested.
7.4. Hypertension
The main function of the large elastic arteries is to serve as capaci-
tance vessels that distend and retract during systole and diastole. Dur-
ing aging, arterial wall elastin laminae become fragmented, thereby
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stiffer than elastic ﬁbers. Such alterations of the arterial wall ECM struc-
ture lead to high systolic and pulse pressure or hypertension, which in-
creases circumferential wall stress, elastic ﬁber further breakdown, and
high risk of local arterial wall fatigue and endothelial damage [152].
Therefore, arterial remodeling has to occur in response to arterial wall
hypertensive hemodynamic changes to adapt to increased mechanical
load, a process involving ECM degradation and reorganization, vascular
wall hypertrophy, and skewed aortic collagen to elastin content [153,
154]. An important feature of hypertensive vascular remodeling is an in-
crease in themedia/lumen ratio, which can occurwith orwithout vessel
growth (e.g. hypertrophic and eutrophic) due to changes in SMC and
ECM components [155,156]. The stiffer the artery, the more pressure
is required to distend the wall, a pathological change relying mainly
on the expression, deposition, and functional construction of elastin
and collagen ﬁbers.
Elastin provides reversible extensibility during cardiac cyclic load-
ing, while collagen provides strength and prevents failure at high pres-
sure. Elastin gene expression and degradation, elastic ﬁber assembly,
and unbalanced elastin synthesis relative to collagens all determine ar-
terialwall stiffness and thickening. For example, arterialwall thickening
is associated with increased elastin degradation products (elastin-
derived peptides), which also stimulate chemotaxis of leukocytes into
the vascular wall, producing proteinases and further contributing to
elastic ﬁber degradation [157].
Reduced elastin level in SVAS patients and elastin haploinsufﬁciency
from Eln+/− mice have increased arterial stiffness and hypertension,
although they have mild cardiac hypertrophy and a normal lifespan
[45,158,159]. As discussed, SVAS is caused by mutations including
point mutations, translocations, and partial deletions within the eln
gene [160–163]. Hypertension is present in large proportion of SVAS pa-
tients usually from early age. Eln+/−mouse arterial stiffness increases
by 7 days after birth,while systolic blood pressure is not signiﬁcantly in-
creased until one week after arterial stiffness, suggesting that increased
large artery stiffness is required for the development of hypertension in
these mice [164]. Expression of human elastin gene in Eln+/−mice in-
creases elastin level to 60–80% of the normal level and reverses the
changes in both arterial stiffness and hypertension [165]. Therefore, de-
fective elastinogenesis in humans and animals could be an initiating
event of hypertension [166,167].
Not only expression, but also altered spatial organization of elastic
ﬁbers, improper assembly, or even skewed synthesis relative to
collagen all compromise vascular elasticity and hypertension. In resis-
tance [168,169] and conduit vessels from spontaneous hypertensive
rats (SHRs) [170,171], more compact elastic laminae with reduced rela-
tive volume of fenestrae are associated with increased vessel stiffness
and correlate with vessel narrowing. Abnormal lamellae organization
was also observed after chronic Ang II infusion [172] and present in neo-
natal SHRs before the establishment of hypertension and alteration in
collagen content [171,173]. Fibulin-5 participates in elastin ﬁber assem-
bly (Fig. 1). Similar to those in aged human arteries [174,175], aortas of
ﬁbulin-5-deﬁcient mice demonstrate abnormal morphology and al-
tered elastic lamella [119,176], accompanied by a signiﬁcant increase
in systolic blood pressure and pulse pressure [119]. In some animals of
induced hypertension, elastin expression is increased but less than col-
lagen, pushing the elastin-to-collagen ratio skewed toward increased
collagen amounts [177]. In monocrotaline-induced pulmonary hyper-
tension, the ratio of elastin to collagens remains constant, but the
newly synthesized elastin does not assemble properly [178].
Collagen is a stiff protein and has the physiological role to limit ves-
sel distension. Excessive collagen in the vascular wall leads to vessel ﬁ-
brosis and overly stiffness. Increased collagen deposition in the vascular
wall has been demonstrated in the conduit and resistance arteries from
patients [179–181], or animals [182,183]with hypertension. In addition
to altered content, collagen undulation, orientation, cross-linking, and
interactions with other ECM elements are fundamental to deﬁningarterial wall stiffness and hypertension. Ang II induces hypertension
by increasing collagen and decreasing elastin content, creating an im-
balance between elastic and rigid ECM components in the vascular
wall [184]. The stiffness of elastin and collagen ﬁbers can be increased
through additional crosslinking by AGEs. Unlike normal crosslinking at
discrete sites and at the end of collagen molecules, AGEs form pro-
tein–protein crosslinks throughout the collagenmolecules in hyperten-
sive arterial wall [185].
In addition to elastin and collagens, several other ECM proteins
have also been implicated in arterial wall structural changes in hyper-
tensive subjects. Arteries from SHRs [186] or from Ang II-infused ani-
mals [187,188] contain increased levels of total ﬁbronectin. Ang II
stimulates proliferative signaling pathway in part through TGF-β [189],
which increases the synthesis of ﬁbronectin and collagens [190,191].
The deposition of ﬁbronectin controls the deposition, organization, and
stability of other ECMs, such as type I and type III collagens [189]. Treat-
ment of hypertensive mice with neutralizing TGF-β antibody or with a
TGF-β inhibitor reduces resistance artery stiffness [66] and collagen de-
position [66,192]. However, since collagen confers rigidity to the vascu-
lar wall, most hypertension therapeutic studies have been focused on
the reduction of vascular collagen content.
8. Conclusions
Vascular wall matrix protein synthesis and metabolism are strictly
regulated to maintain the blood vessel structure and functions in
assisting blood ﬂow diastole and systole. Such blood vessel homeostasis
is organized and protected by vascular wall interlaminal matrix protein
ﬁbers or ﬁlaments, surrounded by layers of vascular cells (SMCs, ECs,
andﬁbroblasts). Chemical,mechanical, and enzymatic injuries interrupt
blood vessel homeostasis, leading to altered structure of existingmatrix
proteins or changes in the production of newly synthesized matrix pro-
teins, their proteolytic bioactive fragments, and alternatively spliced
variants from vascular cells. As a consequence, blood vessels may nar-
row (e.g. atherosclerosis) or become stiff (hypertension) and easy to
rupture, or they may expand (e.g. aneurysms) or become tortuous
(e.g. varicose veins). Interactions amongdifferentmatrix proteins or be-
tween matrix proteins and neighboring vascular cells may prevent or
progress the destruction of vascular wall matrix, depending on the
timing of vascular wall development and on the types of cells and ma-
trix proteins or fragments. Injury or inﬂammatory mediators often
yield uncontrolled expression of proteolytic enzymes that directly affect
the accumulation of matrix proteins and the production of bioactive
matrix peptides, a potential future focus of research in controlling effec-
tively vascular wall matrix remodeling in human vascular diseases.
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